Latest net income for SVA: $14M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Dec 2023
Trailing 12 months ending Dec 2023
Loading...
Loading...
Sinovac Biotech, (SVA) currently reports a net income of $14M as of December 2023. That compares with $8.6B in the prior-year period — down 99.8% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Sinovac Biotech,'s net income history and peer comparisons.
Sinovac Biotech,'s net income decreased from $8.6B to $14M — a 99.8% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Sinovac Biotech,'s net income of $14M is lower than the Healthcare sector average of $16B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Sinovac Biotech, reported $14M in net income as of December 2023. That compares with $8.6B in the prior-year period — down 99.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.